Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dove Keith

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Future Oncology (London, England)|October 8, 2024
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancerCharles D Lopez, Adel Kardosh, Emerson Y Chen, et al.
Cancer Discovery|March 17, 2021
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical OutcomeShannon M Liudahl, Courtney B Betts, Shamilene Sivagnanam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic CancerAndrew E Hendifar, Viswesh Krishna, Vrishab Krishna, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwayMotoyuki Tsuda, Dove Keith, Colin J Daniel, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Future Oncology (London, England)|October 8, 2024
CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancerCharles D Lopez, Adel Kardosh, Emerson Y Chen, et al.
Cancer Discovery|March 17, 2021
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical OutcomeShannon M Liudahl, Courtney B Betts, Shamilene Sivagnanam, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic CancerAndrew E Hendifar, Viswesh Krishna, Vrishab Krishna, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwayMotoyuki Tsuda, Dove Keith, Colin J Daniel, et al.
Pageof 3